Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?

• DOI: 10.1128/aac.02174-18
• Publication Date: 2019-03-20T12:05:33Z
• Authors: Christine Sekaggy...; Maxwell Chirehwa; Joseph Musaazi; Amrei von Braun; Allan Buzibye; Daniel Muller; Ursula Gutteck; Ilaria Motta; Andrea Calcagno; Jan S. Fehr; Andrew Kambugu; Barbara Castelnuovo; Mohammed Lamorde; Paolo Denti
• Keywords: Pharmacology; 0301 basic medicine; Antitubercular drugs; Monolix; Pharmacokinetics; Pharmacometrics; 610 Medicine & health; 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI); 2725 Infectious Diseases; 3. Good health; 10234 Clinic for Infectious Diseases; 03 medical and health sciences; 3004 Pharmacology; Infectious Diseases; 540 Chemistry; 2736 Pharmacology (medical); Pharmacology (medical); 10038 Institute of Clinical Chemistry

Antituberculosis drugs display large pharmacokinetic variability, which may be influenced by several factors, including body size, genetic differences, and drug-drug interactions. We set out to determine these factors, quantify their effect, and determine the dose adjustments necessary for optimal drug concentrations.